Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C24H30N8O5.C5H9NO4 |
| Molecular Weight | 657.6749 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCC(O)=O)C(O)=O.OC[C@H]1CN(CC2=CNC3=C2N=CNC3=O)CC1O[C@H]4CN(CC5=CNC6=C5N=CNC6=O)C[C@@H]4CO
InChI
InChIKey=QGTAIFAWRXBESU-MECDXXGSSA-N
InChI=1S/C24H30N8O5.C5H9NO4/c33-8-15-5-31(3-13-1-25-20-18(13)27-11-29-22(20)35)7-17(15)24(37)10-32(6-16(24)9-34)4-14-2-26-21-19(14)28-12-30-23(21)36;6-3(5(9)10)1-2-4(7)8/h1-2,11-12,15-17,25-26,33-34,37H,3-10H2,(H,27,29,35)(H,28,30,36);3H,1-2,6H2,(H,7,8)(H,9,10)/t15-,16-,17?,24?;3-/m10/s1
Ulodesine (BCX4208) is a new, orally active, highly potent inhibitor of purine nucleoside phosphorylase (PNP) for the treatment of hyperuricemia and gout. Inhibition of PNP reduces the substrates available for XO to form uric acid. The drug is currently under development for the management of hyperuricemia in chronic gout. Two Phase II clinical trials have shown promising results regarding urate-lowering effect in both as monotherapy and in combination with allopurinol. Ulodesine shows no interaction with CYP450 isoforms and has no hepatic metabolism; therefore, no drug interactions were expected. Following the successful outcome of the Phase IIb clinical trial, Phase III development of ulodesine is planned. One concern regarding the use of ulodesine is its impact on T cells. Lack of PNP is associated with immunodeficiency and autoimmune disorders.
Approval Year
Sample Use Guides
In the 12-week randomized controlled trial, in
82 gout patients, the response rates to 5, 10, 20 and 40 mg ulodesine (BCX4208) compared with allopurinol 300 mg were 45, 33, 39 and 49%, respectively
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
WSH2FH5UJL
Created by
admin on Wed Apr 02 21:20:58 GMT 2025 , Edited by admin on Wed Apr 02 21:20:58 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
